Patient flow
A detailed patient selection is shown in Figure 1S .
Use of local conventional cTn values and hs-cTnT values for adjudication of final diagnoses
The cTn assays used clinically in most of the participating institutions changed during the study from a conventional cTn assay to the hs-cTnT assay. In order to take advantage of the of the higher sensitivity and higher overall diagnostic accuracy offered by the hs-cTnT assay, patients were adjudicated using the hs-cTnT values in all patients. In patients in whom clinically a conventional cTn assay was used, the conventional cTn values and the hs-cTnT values were available for the adjudication.
In patients in whom clinically the hs-cTnT assay was used, only the hs-cTnT values were available for the adjudication.
The following conventional cTn assays were used: For the Roche cTnT 4 th generation assay, the 10% CV level is 0.035ug/l. The laboratories of the participating sites reported only two decimals; therefore 0.04ug/l was used as a cut-off for myocardial necrosis. In order to fulfil the criteria of a significant change (30% of 99 th percentile or 10% CV level), a patient would e.g. need to have a level of <0.01ug/l at presentation and 0.04ug/l at 6h. A patient would also qualify if the first level is 0.02ug/l and the second 0.04ug/l. A patient would not fulfil the criteria if the first level is 0.03ug/l and the second is 0.04ug/l. If the first level is 0.04ug/l, the second level needs to be at least 0.06ug/l.
For the Abbott Axsym cTnI ADV, the 10% CV level is 0.16ug/l. A patient having 0.16ug/l at presentation would meet the criteria for significant change if the second was ≥0.21ug/l. A patient having <0.12ug/l at presentation (limit of detection) would qualify if the second is >0.16ug/l.
For the Beckmann Coulter Accu cTnI, the 10% CV level is 0.06ug/l. A patient having 0.06ug/l at presentation would qualify if the second is ≥0.08ug/l. A patient having 0.05 at presentation would qualify if the second is 0.07ug/l, but not 0.06ug/l. A patient having undetectable cTnI (cTnI<0.01ug/l) at presentation would qualify if the second is ≥0.06ug/l.
Assumption of linearity of absolute changes of hs-cTnT within the first hours
The assumption of linearity of absolute changes within the first hours is based on 
Mismatches in the adjudicated diagnosis requiring involvement of a third cardiologist
In our cohort of 2300 patients there were 95 (4%) mismatches in adjudicated diagnosis between the two cardiologists requiring involvement of a third cardiologist, Of these, 23 patients had the final diagnosis of AMI and 72 patients had another diagnosis. These cases were discussed in face-to-face meetings between the 3 cardiologists and a decision was reached by consensus. The same approach was followed in cases of 3 different diagnoses.
Short-term changes in cardiac troponin in patients with markedly elevated levels at presentation
Patients with a single markedly elevated cTn level and otherwise "clear" diagnosis of AMI including unequivocal ECG and coronary angiography findings were adjudicated to have AMI. This scenario fortunately was infrequent, but did exist. The adjudicating cardiologist at all times had the option to classify the patient to the category "chest pain of unknown cause" in case the available information was not sufficient to reliably diagnose or exclude AMI. While the rise and/or fall criteria are important to differentiate AMI from causes of chronic cardiomyocyte damage, it is of much less importance in patients with markedly elevated cTn levels (e.g. 50-times the 99 th percentile), as the positive predictive value of the markedly elevated cTn level (e.g.
50-times the 99 th percentile) on its own is already above 90% 2 and approaches 100%
when combined with typical ECG and coronary angiography findings. The documentation of changes of cTn is not mandatory in these patients, as the differentiation from chronic cTn elevation is not a matter of concern. Therefore, as also suggested by the ESC Biomarker study group 3 , a patient with a clear AMI would still be classified AMI in case of only one markedly elevated cTn level available, as long as all other information (ECG findings, coronary angiography findings, echo findings) supported the diagnosis of AMI. 
SUPPLEMENTAL RESULTS

Disagreement in adjudicated final diagnosis in inconsistent diagnosis
Diagnostic accuracy for the diagnosis acute myocardial infarction of the different assays
Informations about diagnostic accuracy of all the used c-Tn assays provided in table 1S.
Baseline levels of hs-cTnT Roche and hs-cTnI Abbott according to final diagnosis
In hs-cTnI Abbott, 15.4% of baseline values were below the LOD of 1.9ng/L, 57.9%
were in the range between LOD and the 99th percentile of 26.2ng/L (73.3% below 99th P) ( Figure 2S ). Corresponding percentages in hs-cTnT Roche were 30.1%
below LOD of 5ng/L and 35.3% between LOD and 99th percentile of 14ng/L (65.5% below 99th P). In conclusion, there were more of hs-cTnI Abbott values detectable, but in general the assay was less predictive for AMI than hs-cTnT Roche.
Subgroup analysis regarding potential pre-analytical contributors
In 1355 patients parallel measurements of hs-cTnT and s-cTnI-ultra (Siemens) were performed from the same tube and on the same day. In this subgroup findings were similar to that of the overall cohort. AMI was the adjudicated diagnosis in 294 patients (22%). Among patients with an adjudicated diagnosis of AMI levels of hs-cTnT and s-cTnI levels correlated closely (r=0.802, p<0.001). Among these, 53 patients (18%) had inconsistent diagnoses using the approved uniform CDV. Nearly all of these inconsistencies were related to under-diagnosis of AMI with s-cTnI-ultra. Using the s-cTnI-ultra biological-equivalent CDV for hs-cTnT (9.4ng/l instead of 40ng/l) reduced inconsistencies regarding the diagnosis of AMI from 19% to 9% (p<0.001). In 101 patients measurements of hs-cTnI and hs-cTnT were performed from fresh samples.
Again, findings were similar to that in the overall cohort ( Figure 3S ).
Infarct size in patients with inconsistent AMI diagnoses
Median c-Tn values in patients with inconsistent diagnoses of AMI were lower than in patients with consistent AMI diagnoses, indicating that infarct size was smaller in patients with inconsistent diagnoses (Table 2S ). This result was consistent in all comparisons between the different assays. 
Tables
